Biodesix stock target cut to $2 by TD Cowen, retains buy rating

On Wednesday, TD Cowen’s analysts adjusted their outlook on Biodesix shares (NASDAQ:BDSX), reducing the price target from $3.00 to $2.00, while still maintaining a Buy rating on the stock. The revision followed Biodesix’s first-quarter earnings miss and a subsequent downward revision of their financial guidance, attributed primarily to challenges associated with their sales force. The stock has experienced significant pressure, falling over 75% in the past year, with a particularly sharp decline of 15% in the past week alone. InvestingPro data shows the stock’s RSI currently indicates oversold conditions, potentially presenting an opportunity for value investors.

The company’s recent performance has been affected by issues within the sales team, which also had a negative impact on the projections for 2024. According to TD Cowen, the problems stemmed from a combination of staff departures and a slower-than-expected pace in hiring new primary care physician (PCP) representatives. These difficulties contributed to the lower-than-anticipated results for the first quarter. Despite these challenges, the company maintains a healthy gross profit margin of 78% and has demonstrated strong revenue growth of 45% over the last twelve months.

TD Cowen emphasized the importance of consistent quarterly performance as a key factor for investor confidence in Biodesix. Despite the recent setbacks, the firm expressed continued optimism about the company’s prospects. The analysts highlighted the unique utility and the appealing total addressable market (TAM) for Biodesix’s lung diagnostics portfolio. With a market capitalization of just $35 million and a current ratio of 2.76, the company maintains strong liquidity to meet its short-term obligations. For deeper insights into Biodesix’s financial health and growth prospects, InvestingPro subscribers can access comprehensive analysis and 8 additional ProTips.

Biodesix specializes in diagnostic solutions for lung disease, offering products that aim to improve patient outcomes and reduce healthcare costs. The company’s performance and investor sentiment are closely tied to the effectiveness and expansion of its sales force, which directly impacts its ability to market and sell its diagnostic offerings.

The analysts’ statement underscored their belief in the inherent value and potential of Biodesix’s offerings, despite the near-term challenges faced by the company. The lowered price target reflects adjustments based on the latest financial data and market conditions, while the maintained Buy rating indicates a positive long-term outlook for the company’s stock.

In other recent news, Biodesix reported a 21% year-over-year increase in total revenue for the first quarter of 2025, reaching $18 million. Despite this growth, the company revised its full-year revenue guidance downward to $80-85 million, which impacted investor sentiment. The company’s net loss improved by 18% year-over-year, totaling $11.1 million. Canaccord Genuity maintained its Buy rating on Biodesix shares but reduced the price target from $2.50 to $1.50, citing the first-quarter results that fell short of expectations. Meanwhile, William Blair downgraded Biodesix’s stock rating from Outperform to Market Perform, following the company’s downward revision of its full-year revenue guidance. Biodesix has introduced a new territory-based sales structure and aims to expand its sales team from 65 to 95 representatives by the end of 2025. The company is optimistic about achieving adjusted EBITDA positivity by the fourth quarter of 2025. Despite challenges, analysts believe Biodesix’s stock is trading at a discounted valuation, with potential for growth as the company progresses toward its targets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.